Tinurilimab  (Synonyms: BAY 1834942)

Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system^[1].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Humanized

Tinurilimab (Bay 1834942) binds to human and cynomolgus monkey CEACAM6 with monovalent dissociation constants of K_D of 13 nM and 31 nM, respectively. Tinurilimab is highly selective for human CEACAM6, as it is unable to bind to human CEACAM1, CEACAM3, or CEACAM5^[1].
The half-maximal binding EC₅₀ values for Tinurilimab are determined by flow cytometry in a panel of CEACAM6-expressing cancer cell lines. For Tinurilimab, the EC₅₀ values are in the range of 0.15 nM (PA-TU-8902) to 5 nM (HCC2935)^[1].
Tinurilimab (0-15 μg/mL) blocks the binding of recombinant CEACAM6-Fc to CEACAM1-coated plates in a dose-dependent manner^[1].
Tinurilimab (30 µg/mL) increases type 1 cytokine secretion and the cytotoxic capacity of tumor-specific T cells^[1].
Blockade of CEACAM6 by Tinurilimab (0.01-1000 µg/mL) restored T cell activity in a dose-dependent manner, as evidenced by increased IFN-γ secretion by survivin T cells co-incubated with recombinant CEACAM6-loaded beads^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.76 kDa

2226224-30-0

Liquid

Colorless to light yellow

[Tinurilimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• [1]. Pinkert J, et al. T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. Oncoimmunology. 2021 Dec 30;11(1):2008110.  [Content Brief]